News Breaks |
|
|
| November 2, 2012 |
| 09:03 EDT |  | PKI, AFFX, LH, RHHBY, LIFE, ENZ | Enzo Biochem says jury declares Life Technologies infringed patents Enzo Biochem (ENZ) reported that the jury in the Enzo action entitled Enzo Biochem, Inc. et al. vs. Applera Corp. and Tropix Inc. in New Haven, CT Civil Action No. 3:04cv929, has rendered its verdict that Applera Corp., now Life Technologies (LIFE), infringed Enzo’s patents covering pioneering technologies relating to compounds used in DNA sequencing systems to read the genetic code. The jury awarded $48.6M in direct infringement penalties. In addition, a pre-judgment award will be awarded by the Court. Attorneys for Enzo estimate that the addition of the pre-judgment award should add additional recoveries of up to tens of millions of dollars. The jury also found that Life Technologies’ sequencing instruments induced its customers to infringe Enzo’s patent No. 5,449,767. The sales of such instruments are estimated to be $770M. Enzo plans to seek damages based on the jury decision that the sale of Life Technologies’ sequencing instruments induced infringement of Enzo patents. Enzo expects that today’s decision will have a positive impact on the resolution of pending actions that Enzo brought in the U.S. Southern District Court in New York City, which involve additional defendants, patents and contract issues. Defendants in those suits include Amersham PLC, Amersham Biosciences, Roche Diagnostics (RHHBY), PerkinElmer (PKI) , PerkinElmer Life Sciences, Inc, Molecular Probes, Orchid Cellmark (LH) and Affymetrix (AFFX). |
|
|
News For ENZ;LIFE;RHHBY;PKI;LH;AFFX From The Last 14 Days Check below for free stories on ENZ;LIFE;RHHBY;PKI;LH;AFFX the last two weeks. |
|
|
| May 22, 2013 |
| 10:33 EDT |  | RHHBY | Bristol-Myers jumps after Citi ups rating on cancer potential
Subscribe for More Information |
|
| 10:00 EDT |  | RHHBY | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 06:02 EDT |  | RHHBY | Roche upgraded to Buy from Neutral at Citigroup
Subscribe for More Information |
|
| May 21, 2013 |
| 20:03 EDT |  | RHHBY, LIFE | Roche, Sigma-Aldrich teamed for Life bid, Reuters says
Subscribe for More Information |
|
| 10:00 EDT |  | LIFE | On The Fly: Analyst Downgrade Summary Today's noteworthy downgrades include: Acquity Group (AQ) downgraded to Neutral from Buy at Roth Capital... Beazer Homes (BZH) downgraded to Neutral from Buy at Sterne Agee... CME Group (CME) downgraded to Neutral from Outperform at Macquarie... Carnival (CCL) downgraded to Neutral from Buy at UBS... Coach (COH) downgraded to Equal Weight from Overweight at Morgan Stanley... Deutsche Bank (DB) downgraded to Neutral from Overweight at JPMorgan... First Republic Bank (FRC) downgraded to Hold from Buy at Jefferies... Franklin Resources (BEN) downgraded to Neutral from Outperform at Macquarie... Life Technologies (LIFE) downgraded to Underperform from Outperform at CLSA... Oil States (OIS) downgraded to Neutral from Buy at Sterne Agee... Raymond James (RJF) downgraded to Market Perform from Outperform at Wells Fargo... VF Corp. (VFC) downgraded to Market Perform from Outperform at Wells Fargo... WellCare (WCG) downgraded to Neutral from Buy at Goldman... Huaneng Power (HNP) downgraded to Neutral from Buy at Citigroup... Comerica (CMA) downgraded to Neutral from Buy at DA Davidson... Beazer Homes (BZH) downgraded at Sterne Agee... Oil States (OIS) downgraded at Sterne Agee... eHealth (EHTH) downgraded to Neutral from Buy at Lazard Capital... Carnival (CCL) downgraded to Market Perform from Outperform at Wells Fargo... Warner Chilcott (WCRX) downgraded to Neutral from Positive at Susquehanna. |
|
| 06:26 EDT |  | LIFE | Life Technologies downgraded to Underperform from Outperform at CLSA CLSA downgraded Life Technologies citing the takeout bid by Thermo Fisher. Price target is $76. |
|
| May 20, 2013 |
| 17:26 EDT |  | RHHBY | Regeneron, Genentech, Sanofi enter into 'Zaltrap agreement'
Subscribe for More Information |
|
| 17:20 EDT |  | RHHBY | Regeneron,, Bayer, Genentech resolve certain patent disputes
Subscribe for More Information |
|
| 14:06 EDT |  | PKI | Illumina says Verinata reimbursements exceeding expectations At the UBS Healthcare Conference earlier today, Illumina (ILMN) CFO Marc Stapley said adoption for the company's Verinata prenatal test has met expectations, while reimbursement for the test has exceeded expectations, adding that its relationship with PerkinElmer (PKI) has allowed the company to obtain significant coverage decisions. In afternoon trading, shares of Illumina are up $1.48, or 2.06%, to $73.48. |
|
| 06:01 EDT |  | AFFX | Affymetrix CFO Tim Barabe to retire from company effective June 28.
Subscribe for More Information |
| |
| May 16, 2013 |
| 08:17 EDT |  | PKI | PerkinElmer has a conference call hosted by JPMorgan JPMorgan Analyst Peterson will host a conference call with CEO Rob Friel and CFO Andy Wilson on May 16 at 11 am. |
|
| May 15, 2013 |
| 17:36 EDT |  | LIFE | Paulson gives quarterly update on stakes
Subscribe for More Information |
|
| 15:59 EDT |  | RHHBY | Roche exploring sale of blood glucose meters unit, Reuters says
Subscribe for More Information |
|
| 12:13 EDT |  | RHHBY | Roche management to meet with Jefferies Meeting to be held in London on May 17 hosted by Jefferies. |
|
| 11:38 EDT |  | RHHBY | Roche says FDA approves Tarceva tablets for specific lung cancer situation
Subscribe for More Information |
|
| 06:36 EDT |  | PKI | Illumina to partner for automation of sample preparation kits
Subscribe for More Information |
|
| May 14, 2013 |
| 16:55 EDT |  | RHHBY | FDA approves Roche's cobas EGFR mutation test with Tarceva
Subscribe for More Information |
|
| 05:44 EDT |  | LIFE | Banks work deals from both sides of the field, WSJ reports
Subscribe for More Information |
|
| May 13, 2013 |
| 08:55 EDT |  | RHHBY | Biosimiliar drug bill to be taken up in Senate, LA Times reports
Subscribe for More Information |
|
| 07:30 EDT |  | RHHBY | TechConnect to host a summit 2013 National Innovation Summit is being held in Washington, D.C. on May 12-16. |
| |
|
|
|
|